Previous Close | 146.05 |
Open | 148.32 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 142.65 - 150.78 |
52 Week Range | 118.16 - 152.06 |
Volume | |
Avg. Volume | 3,977 |
Market Cap | 232.269B |
Beta (5Y Monthly) | 0.19 |
PE Ratio (TTM) | 35.83 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 2.86 (1.97%) |
Ex-Dividend Date | Feb 22, 2024 |
1y Target Est | N/A |
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual M
CAMBRIDGE, United Kingdom, April 25, 2024--Q1 Earnings Release (25 April 2024)
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).